Key Segmentation
By Drug Class
- Second-Generation Antipsychotics
- First-Generation Antipsychotics
- Third-Generation Antipsychotics
By Route of Administration
- Injectable Antipsychotics
- Oral Antipsychotics
By Disease Subtype
- Paranoid Schizophrenia
- Hebephrenic Schizophrenia
- Catatonic Schizophrenia
- Undifferentiated Schizophrenia
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Schizophrenia Drugs Market is expected to grow at a CAGR of 4.95% from 2026 to 2035.
The Schizophrenia Drugs Market was valued at USD 8.92 Billion in 2025.
Rising global prevalence of schizophrenia combined with growing adoption of long-acting injectable formulations is the major growth factor.
The Second-Generation Antipsychotics segment held approximately 73.05% share in 2025.
North America held the largest share of the Schizophrenia Drugs Market in 2025, at approximately 62.91%.
